Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
ABSTRACT: The tumor phenotype is associated with the rearrangement of genetic information and the altered expression of many gene products. In this review, genes associated with the tumor phenotype have been arranged on the human gene map and indicate the extent to which the tumor phenotype involves the human genome. Nonrandom chromosomal aberrations that are frequently observed in tumors are presented. Altered metabolic demands of the tumor cell are reflected in altered gene expressions of a wide range of enzymes and other proteins, and these changed enzyme patterns are described. The study of oncogenes increasingly suggests that they may be significant in certain cancers, and the assignment of these genes has been tabulated. The biochemical and metabolic changes observed in tumors are complex; studying the patterns and interactions of these changes will aid our genetic understanding of the origins and development of tumors.

INTRODUCTION

Tumors are associated with a large number of chromosomal and biochemical changes, including altered patterns of enzyme activities and isozyme expression, cell surface and secreted proteins, and various abnormalities in chromosome structure and number. These changes reflect the altered expression of many genes; however, it is not known which, if any, trigger tumor development or are a consequence of tumorigenesis.

Individual tumors are likely caused by a single or small number of genetic changes, while the initiation of tumorigenesis is followed by numerous biochemical changes that probably interact in complex ways to produce the final tumor phenotype. These biochemical changes reflect altered gene expressions, and it is important to determine which genes have altered expressions, how they are altered, and to look for patterns of altered expression in order to understand the various interactions between genes and gene products that result in the tumor phenotype.

Some tumors are associated with specific chromosomal rearrangements, and these are included in this review. The chromosomal locations of those genes with altered expressions of gene products in tumors are also described. The study of oncogenes may provide new insights into the genetic control of tumors, and those oncogenes that have been mapped to specific chromosomes are also reported. With this information, a map of human genes and chromosomal regions involved in tu-
morigenesis has been generated. The study of biochemical changes in tumors, of chromosomal regions of particular interest in tumor genetics, and of the involvement of oncogenes in the disease will aid further investigation and understanding of tumorigenesis.

CANCERS ASSOCIATED WITH CHROMOSOMAL CHANGES

Tumor cells commonly express chromosomal changes either with the loss or gain of whole chromosomes or with their rearrangement by translocations, deletions, etc. Although some tumors are associated with nonrandom chromosomal changes, other changes appear to be nonspecific, and most tumors have a range of different chromosomal defects associated with them. Indeed, tumor cells grown in culture often accumulate multiple chromosomal changes. However, some cancers have specific associations with certain mutations or chromosomal changes (Table 1) [1–3]. For a number of those chromosomal abnormalities that have been localized to specific chromosome bands, certain genes have also been mapped to the same regions [4]. Analysis of these genes may therefore be valuable in characterizing the specific chromosomal breakpoints, and may perhaps aid the study of the various tumors.

The Philadelphia (Ph1) chromosome in chronic myeloid leukemia is the result of a t(9;22)(q34;q11) translocation; although in a small percentage of cases, the Ph1 chromosome is associated with unusual or complex translocations. The gene for aconitase-2 (ACO2) is on chromosome #22 (q11→q13), as are the proto-oncogene c-sis and the genes for the immunoglobulin λ-chain, constant and variable regions (IGLC, IGLV) [4]. Some genes have been mapped to the q34 band of chromosome #9, namely, the ABO blood group (ABO), adenylate kinase-1 (AK1), and the nail-patella syndrome (NPS1).

Burkitt's lymphoma is primarily associated with a t(8;14)(q24;q32) translocation. However, other translocations that have been reported in a minority of cases are t(2;8)(p12;q24) and t(8;22)(q24;q11), suggesting that a breakpoint in 8q24 is crucial for the disease [1–3]. Two human proto-oncogenes that have been mapped to chro-

| Table 1 Cancers associated with specific chromosomal abnormalities [1–4] |
|---------------------------|---------------------------|---------------------------|
| Cancer                   | Chromosome                | Gene markers\(^a\)       |
| Acute promyelocytic leukemia (APL) | t(15;17)(q26;q21) | 15: MPI, PKM2, B2M \(17: \)TK1, GALK, A12M4 |
| Burkitt’s lymphoma (BL)   | t(8;14)(q24;q32)          | 8: MYC, FNS               |
|                           | t(2;8)(p12;q24)           | 14: IGH, EBNA             |
|                           | t(8;22)(q24;q11)          | 2: IGK, FN                |
| Chronic myeloid leukemia  | t(9;22)(q34;q11)          | 9: ABO, AK1, NPS1         |
|                           | (Philadelphia [Ph\(^1\) chromosome) | 22: ACO2, SIS, IGLC, IGLV |
| Familial renal cell carcinoma | t(3;8)(p21;q24)         | 3: ACY1, GLB1             |
| Ovarian cancer            | t(6;14)(q21;q24)          | 6: SOD2                   |
| Retinoblastoma-1 (RB1)    | del 13q14                 | 13: ESD                   |
| Small cell lung cancer (SCLC) | del 3p14→p23          | 11: INS, FN*, CAT         |
| Wilms’ tumor/aniridia complex (WAGR) | del 11p13              |                           |

\(^a\)Gene markers: The genes potentially involved in tumorigenesis together with those localized to the chromosomal regions involved in the translocations or deletions are listed here. MPI, mannose phosphate isomerase; B2M, β2-microglobulin; ACO2, aconitase (mitochondrial); ABO, ABO blood group; NPS1, nail-patella syndrome type 1; ACY1, aminocacylase-1; FN, FN*, FNS, genes in the fibronectin system. The designations of the other gene markers are described in Table 12. For additional genes mapped to these chromosomes, see refs. 80 and 93.
mosome #8 are c-mos (8q22) and c-myc (8q24) [5, 6, 87]. A gene in the fibronectin system (FNS) has also been mapped to chromosome #8. The translocations with chromosome #8 are not random, but involve chromosome #14, and to a lesser extent, chromosomes #2 and #22. It is of interest to note that an Epstein-Barr virus nuclear antigen (EBNA) has been mapped to chromosome #14 [4], with Epstein-Barr virus being associated with Burkitt's lymphoma in Africans [7]. Also, the genes for the immunoglobulin heavy chains (IGH) are to be found on chromosome #14; and for at least one Burkitt's lymphoma cell line, the breakpoint on chromosome #14 occurs in the IGH region [8]. The genes for the immunoglobulin kappa chains (IGK) are on chromosome #2 (with IGKV on 2p12→cen), while the immunoglobulin lambda chains (IGLC and IGLV) are on chromosome #22 [4]. Another human proto-oncogene, c-sis, is also found on chromosome #22 [9]. Further study should determine what significance these loci might have in Burkitt's lymphoma.

Acute promyelocytic leukemia (APL) is associated with translocation t(15;17)(q26;q21) [2-4]. Mannosephosphate isomerase (MPI), pyruvate kinase (M2) (PKM2), and β2-microglobulin (β2m) are all on the region 15q22→qter, whereas thymidine kinase-1 (TK1), adenovirus-12 chromosome modification site 17 (A12M4), and galactokinase (GALK) are all on chromosome #17q21→q22.

The Wilms' tumor—aniridia, genitourinary abnormalities, and mental retardation—disorder (WAGR) is associated in some cases with a constitutional (i.e., in-born) deletion in 11p13 [4]. The gene for catalase (CAT) is also found on the 11p13 band, with the enzyme being deficient in some cases of WAGR [10]. The use of catalase may help in the study of this disorder. Insulin (INS) maps to the same region (11p14→p15)[11], and another gene in the fibronectin (FN) system is also on chromosome #11 [86].

There is a specific association between retinoblastoma (RB1) and a constitutional deletion in the 13q14 band [12]. The gene for esterase-D (ESD) has also been mapped to 13q14, with the enzyme being deficient in RB1 patients [13]. The analysis of esterase-D should therefore be of value in the study and diagnosis of retinoblastoma.

Whang-Peng et al. [14] report that, in human small cell lung cancer (SLC), there is a specific deletion in the p14→p23 region of chromosome #3. Marker genes also found in this region are aminoacylase-1 (ACY1, 3p21) and β-galactosidase (GLB1, 3p21→q21). ACY1 is deleted in SCLC and could therefore be used as a marker for the tumor.

Wake et al. [15] report a specific translocation, t(6;14)(q21;q24), in ovarian cancer. Superoxide dismutase-2 (SOD-2) is also found on 6q21, while other genes mapped to 14q24 have been described above.

A family with inherited renal cell carcinoma has been reported that exhibit a t(3;8)(p21;q24) translocation [16]. The gene markers associated with the 3p21 and 8q24 regions have already been discussed above. However, other cases of familial or nonfamilial renal cell carcinoma studied do not have a t(3;8) translocation.

For a number of tumors there are nonrandom associations with particular chromosomal abnormalities (Table 2). Alterations in chromosome #1 are associated with a large number of different cancers (Table 2). In a study of 218 cancers with breakpoints in chromosome #1 [19], 50% of cases had breakpoints in the 1p21→q21 region, 15% in the 1p22→p32 region, 14% in the 1q31→q32 region, and 8% in the 1p36 band. Genes mapped to these regions include adenovirus-12 modification site 1A (A12M2) and enolase-1 (ENO1, both 1p36), uridine monophosphate kinase (UMPK, 1p32), phosphoglucomutase-1 (PGM1, 1p22.2), phosphogluconate dehydrogenase (PGD, 1pter→p34), DNA satellite 3 (D1Z1, 1q12), adenovirus-12 modification site 1B (A12M3, 1q21), UDP glucose pyrophosphorylase-1 (UGP1, 1q21→q22), α-amylase (AMY1, AMY2, 1p21), and guanylate kinase-1 (GUK1,
Table 2  Cancers with nonrandom associations with specific chromosomal abnormalities [1, 17, 18]

| Cancer                                | Chromosomes       |
|---------------------------------------|-------------------|
| Acute myeloid leukemia (AML)          | 7, 8, 17, 21      |
| Chronic myeloid leukemia (CML)        | t(9;22) with other aberrations: 8, 17, 22 |
| Polycythemia vera (PV)                | 1, 8, 9, 20       |
| Myeloproliferative diseases (MD)      | 5, 7, 8           |
| Acute lymphocytic leukemia (ALL)      | 1, 6, 8, 14, 21, 22 |
| Chronic lymphocytic leukemia (CLL)    | 12, 14, 17        |
| Monoclonal gammopathies (MG)          | 1, 3, 11, 14      |
| Malignant lymphomas (ML)              | 1, 3, 14          |
| Carcinomas                            | 1, 3, 8           |
| Meningiomas                           | 8, 22             |
| Other neurogenic tumors               | 1, 22             |
| Malignant melanomas                   | 1, 3, 6, 7, 9, 11 |
| Benign epithelial tumors              | 8, 14             |

* Gene markers mapped to each of these chromosomes have been tabulated [80, 93].

1q32→q42) [4, 80]. Use of these markers should aid the further study of the significances of these chromosome regions.

About 10% of cases with acute myeloid leukemia (AML) have a t(8;21) (q22;q22) translocation [1, 4]. The proto-oncogene c-mos is on 8q22, while superoxide dismutase (SOD1) has been localized to region 21q22. The various subtypes of AML reflect different stages of differentiation of granulocytic cells, and they are associated with different chromosomal abnormalities [e.g., the myeloblast with t(8;21) and the promyelocyte with t(15;17)]. Thus, different chromosomes, and by implication different genes, are significant in tumorigenesis at different stages of granulocyte differentiation.

In about 70% of the meningioma cases studied, a deletion of chromosome #22 is observed [20]. Genes that have been mapped to chromosome #22 are described above. There is also a nonrandom association between chromosome 1p− deletions and neuroblastoma [18].

**MAPPING OF GENES CODING FOR ENZYMES ALTERED IN TUMORS**

Characteristic changes in various enzymes are observed in tumors as compared to the corresponding normal tissues [for reviews, see references 21–24]. These changes occur in both specific enzyme activities and in isozyme patterns. The metabolic changes are associated with altered growth patterns of tumors, specifically with the change of a differentiated slow-growing tissue to a dedifferentiated fast-growing tumor. The chromosomal locations of the genes of only a few of the affected enzymes are known, and these are scattered widely over the whole genome, as shown in Table 3. The genes with expressions affected in tumors that are not presently mapped (Tables 4 and 5) are also expected to be distributed widely over the genome.

Many of the metabolic changes observed in tumors more closely resemble the corresponding fetal tissue than the original adult tissue (Tables 3–5) [31]. Knox [43] studied 82 enzymes present in normal rat liver and found that 24 enzymes that had low activities in fast-growing hepatomas also had low activities in fetal liver. Forty-two of the 50 enzymes with high activities in hepatomas also had high activities in fetal liver.
| Enzyme                  | Isozyme | Human chromosome assignment | Tissue patterns                          | Tumor patterns                                                                 | References |
|------------------------|---------|-----------------------------|------------------------------------------|---------------------------------------------------------------------------------|------------|
| Adenylate kinase       | AK1     | 9                           | Rat: a minor form                       | Hepatoma and fetal liver: total activity increased.                             | 21, 23     |
|                        | AK2     | 1                           | Rat: muscle, brain, lungs                |                                                                                  |            |
|                        | AK3     | 9                           | Rat: liver, kidney, testis              |                                                                                  |            |
|                        |         |                             |                                          |                                                                                  |            |
| Hexokinase             | HK1     | 10                          | I: brain, kidney, uterus, etc. fetal liver | Rat hepatomas: I ↓ II ↑ III = or IV ↓ Total ↓ Other human and rat tumors have increased activities of isozymes | 21, 22, 24, 25 |
|                        |         |                             |                                          |                                                                                  |            |
| Pyruvate kinase        | PK      | L: major rat liver form, also kidney | Rat hepatomas: L ↓ M2 ↑ Total ↑ Other human and rat tumors have increased M2 and decreased M1 (e.g., brain, colon, rhabdosarcoma) | 12, 22, 24–26 |
|                        | PKM2    | 15                          | M2: minor adult liver form and other tissues, fetal liver and other tissues |                                                                                  |            |
|                        |         |                             |                                          |                                                                                  |            |
| Lactate dehydrogenase  | LDHA    | 11                          | Skeletal muscle, liver, fetal tissues    | Rat hepatoma, B ↑ rabdosarcoma: Total ↑ Most human and rat tumors have increased activity of A (e.g., brain, lung, kidney, breast, digestive tract, thyroid, pancreas, lymph node, etc.) | 21, 23, 25 |
|                        | LDHB    | 12                          | Heart, brain, kidney                    |                                                                                  |            |
| Phosphofructokinase    | PFKF    | 10                          | Fetal and adult liver                   | Hepatoma: L ↓ Tumors of lymph node, gastric, Ehrlich ascites express L           | 22, 23, 25 |
|                        | PFKL    | 21                          |                                          |                                                                                  |            |
|                        | PFKM    | 1                           | Muscle                                   | L-M hybrid molecules ↑ L-M hybrid molecules                                       |            |

(continued)
| Enzyme                 | Isozyme | Human chromosome assignment | Tissue patterns                                      | Tumor patterns | References |
|-----------------------|---------|----------------------------|-----------------------------------------------------|----------------|------------|
| Thymidine kinase      | TK1     | 17                         | Fetal liver                                         | Hepatomas: 1 ↑ | Other tumors have increased TK1, total activity (e.g., rhabdosarcoma, bladder adenocarcinoma, gastrointestinal, Wilms' tumor, etc.) | 22          |
|                       | TK2     | 16                         | Adult liver                                         | Total: ↑       |            |            |
| Isocitrate dehydrogenase | IDH1   | 2                          | NADP-linked: Liver, adrenal                         | Rat hepatoma: 1 ↓ | In rat Ehrlich carcinoma the NAD-linked enzyme is the major form | 21, 23      |
|                       | IDH2    | 15                         | Heart, kidney, (liver)                               |                |            |            |
|                       |         |                            | NAD linked: Muscle, brain, (liver)                   |                |            |            |
| Malate dehydrogenase  | MDH1    | 2                          |                                                     | 1: ↓ 2: ↑ Total: ↓ | In hepatoma, mammary, and other tumors, total activities are similar or decreased compared to normal tissues, with MDH1 ↓, MDH2 ↑ | 21          |
|                       | MDH2    | 7                          |                                                     |                |            |            |
| Glycerol-3-phosphate dehydrogenase | GPD1 | 12                         | Soluble enzyme: Adult liver, muscle                  | ↓              | In hepatomas and many other tumors, GPD1 very low or absent; mitochondrial form similar or slightly elevated Total activities decreased | 21, 22, 24  |
|                       |         |                            | Mitochondrial enzyme: Fetal tissues and many adult tissue including brain, muscle |                |            |            |
| Branched chain aminotransferase | BCT1 | 12                         | I: Rat liver, muscle, kidney, spleen, etc. fetal liver | Rat hepatoma: I ↑ |            | 22–24      |
|                       |         |                            | II: in liver only adult                              | II ↓           |            |            |
|                       | BCT2    | 19                         | III: rat brain only                                  | III ↑          |            |            |
|                       |         |                            |                                                        | Total ↑        |            |            |
| Enzyme/Phosphorylase | Genes | Tissues | Activity
|----------------------|-------|---------|---------------------|
| Glutamate oxalate transaminase | GOT1 10, GOT2 16 | Many tissues | GOT1 increased in hepatomas; total activity variable and may or may not increase |
| Superoxide dismutase | SOD1 21 | Soluble enzyme: All tissues | In human tumors, there is no consistent change in activity (both cytoplasmic and mitochondrial enzymes have Mn SOD in human tissues) |
|                | SOD2 6 | Mitochondrial enzyme: All tissues | All animal tumors have decreased Mn SOD (only found in mitochondria) |
| Glucose-6-phosphate dehydrogenase | G6PD X | | Cu-Zn SOD commonly but not always decreased |
| Phosphogluconate dehydrogenase | PGD 1 | | Activity increased in hepatoma, colon carcinoma, breast cancer |
| Creatine kinase | CKBB 14 | B: Early fetal tissues, adult tissues | Hepatoma: decreased activity |
|                |        | M: Muscle, lung | Colon carcinoma: decreased |
| Uridine phosphorylase | UP 7 | Salivary gland, lung, fetal tissues | Hepatoma, renal: increased activity, Colon carcinoma: decreased |
| α-Amylase | AMY1 1 | Pancreas | AMY1 ↑ lung, ovarian tumors |
|                | AMY2 1 | Pancreas | AMY2 ↑ pancreatic tumors, Hepatoma: decreased activity |
| Ornithine transcarbamylase | OTC X | | |
| Monoamine oxidase | MAOA X | | |
| UDP glucose pyrophosphorylase | UGP1 1 | | |
| Galactokinase | UGP2 2 | | |
| Adenosine deaminase | GALK 17 | | |
| Aryl hydrocarbon hydroxylase | ADA 20 | | |
| Succinate dehydrogenase | ADA 2 | | |
| Catalase | CAT 11 | | |
| Arylsulfatase | ARSA 2 | | |
|                | ARSB 5 | | |

**Note:** (continued)
Table 3  Chromosome assignments of isozymes [4] changed in tumors: Mapped genes (continued)

| Enzyme                                | Isozyme | Human chromosome assignment | Tissue patterns                                      | Tumor patterns                                      | References |
|---------------------------------------|---------|-----------------------------|------------------------------------------------------|------------------------------------------------------|------------|
| Phosphoribosyl pyrophosphate amidotransferase | PPAT    | 4                           | Multiple isozymes in many tissues                    | Rat hepatoma: increased activity                     | 36         |
| Malic enzyme                          | ME1     | 6                           | Multiple isozymes in many tissues                    | ME1: hepatoma, increased activity                    |            |
|                                       | ME4     | 11                          | Multiple isozymes in many tissues                    | ME4: hepatoma, decreased activity                    |            |
| Acid phosphatase                      | ACP1    | 2                           | Multiple isozymes in many tissues                    | In various tumors there are increased activities (e.g., hepatoma, leukemia, different carcinomas) and altered isozyme patterns (e.g., hepatoma, breast adenocarcinoma) | 22         |
|                                       | ACP2    | 11                          | Multiple isozymes in many tissues                    |                                                      |            |
| Esterases                             | ESA4    | 11                          | Multiple isozymes in many tissues                    | Altered isozyme patterns in various tumors (e.g., hepatoma, carcinoma, leukemia) | 22, 23     |
|                                       | ESB3    | 16                          | Multiple isozymes in many tissues                    |                                                      |            |
|                                       | ESD     | 13                          | Multiple isozymes in many tissues                    |                                                      |            |
| β-Hexosaminidase                      | HEXA    | 15                          | Rat adult brain, kidney, colon, etc.                  | Rat hepatoma: B ↓ In many tumors HEXB increases; total activity similar or increases (e.g., colonic tumors, renal and lung carcinomas, AML, CML); activity decreased for ALL, CLL | 22, 36–39 |
|                                       | HEXB    | 5                           | Fetal liver                                          |                                                      |            |
| β-Glucosidase                         | GBA     | 1                           |                                                      | Lung carcinoma: increased activity                   | 37         |
| α-Mannosidase                         | MANA    | 15                          |                                                      | Lung carcinoma, AML, CML: increased activity        | 37, 39     |
|                                       | MANB    | 19                          |                                                      | ALL, CLL: decreased activity                         |            |
| β-Glucuronidase                       | GUSB    | 7                           |                                                      | Lung carcinoma: increased activity                   | 37         |
| β-Galactosidase                       | GLB1    | 3                           |                                                      | Lung carcinoma, AML, CML: increased activity        | 37, 39     |
| Plasminogen activator                 | PLA     | 6                           |                                                      | Increased activity in many human tumors (including lung and breast tumors) | 40         |
| Glyoxalase I                          | GLOI    | 6                           |                                                      | Decreased activity in hepatomas and various other tumors | 41         |
| Glyoxalase II (hydroxyacyl glutathione hydrolase) | HAGH | 16                          |                                                      | Decreased activity in hepatomas and various other tumors | 41         |
A good model system for the study of metabolic patterns in tumors is provided by a series of rat Morris hepatomas that range from slow-growing well differentiated tumors with more nearly normal adult isozyme patterns to fast-growing poorly differentiated tumors with fetal-like isozyme patterns [44]. Much of the work on enzyme activities and isozyme patterns has been done on rat and human hepatomas, which exhibit very similar changes in enzyme patterns. The study of hepatomas is valuable because the liver expresses many differentiated enzyme functions that are often changed in tumors. The enzyme changes observed for hepatomas mostly seem to be generalized metabolic changes, reflecting the process of transformation and increased growth demands on the tumor cells. Hepatomas and other tumors express different isozyme patterns for some enzymes, but these mostly reflect the different fetal and adult isozyme patterns of the respective tissues. The generalized response of metabolic enzymes to tumorigenesis is of interest, especially considering that the initial defects of the various tumors most likely occur in different loci scattered throughout the genome.

The metabolic changes in tumors occur in the key rate-limiting enzymes of different metabolic pathways, such that there is increased growth and decreased catabolism [29, 30]. The isozyme patterns of these enzymes tend to change from the differentiated forms to the dedifferentiated fetal forms. The key enzymes are affected by isozyme and activity changes, such that there is increased growth, e.g., increased glycolysis (with increased hexokinase, phosphofructokinase, pyruvate kinase activities) and decreased gluconeogenesis (with decreased glucose-6-phosphatase, fructose diphosphatase, phosphoenolpyruvate carboxykinase, and pyruvate carboxylase activities). There is also increased protein synthesis and decreased catabolism, increased nucleic acid synthesis and decreased degradation, and so on. In general, the metabolic pathways involved in synthesis and growth increase over the catabolic degradative pathways as tumor growth rates increase. Some of these known changes are listed in Tables 3-5. As more of these and other genes altered in tumors are mapped, our understanding of the patterns and interactions of genetic change in tumorigenesis will increase. It is readily apparent, however, that there is no obvious pattern to gene location in the genome. Enzymes from the same metabolic pathways are found on different chromosomes, as are enzymes with similar functions. The level of control of isozyme changes in tumors is not at the chromosomal level, but is apparently at the individual gene level.

**OTHER CHANGES**

Other gene products are also implicated in the tumor phenotype, either in altered gene expression or in the involvement of the gene product with some aspect of the tumor cell. Many of these genes have been assigned to specific chromosomes.

**Hormones**

The abnormal production of polypeptide hormones is associated with certain tumors, with the pattern of hormone synthesis apparently reflecting the embryologic background of the tumor in question [45]. Increased hormone synthesis may be a secondary effect of tumorigenesis rather than a primary cause. Thus, tumors whose origins derive from the neural crest tend to secrete hormones such as insulin, calcitonin, proopiocortin, ACTH, vasopressin, glucagon, serotonin, catecholamines, and others. Tumors with embryologic origins in the endoderm or mesoderm, however, mostly secrete hormones such as parathyroid hormone, the gonadotropins, chorionic somatomammotropin, prolactin, growth hormone, etc. The chromosomal
| Enzyme                | Isozyme | Tissue patterns          | Tumor patterns                                                                 | References |
|----------------------|---------|--------------------------|-------------------------------------------------------------------------------|------------|
| Alkaline phosphatase | Regan   | Placenta                 | Found in various tumors, mainly of ovary, testis, pancreas                    | 22         |
|                      | Non-Regan | Fetal tissues           | Found in many tumors                                                          |            |
|                      | Hepatoma  | Fetal and adult intestine, FL amnion | Found in hepatomas                |            |
| Aldolase              | A       | Sole form in muscle; also in most other tissues (e.g., spleen, kidney, lung etc.); predominant form in fetal liver | Human and rate hepatomas A ↑ → Various tumors express fetal patterns that may be the same as adult (e.g., sarcoma, A; glioblastoma, A and C) or different from adult (e.g., renal carcinoma, B ↓; meningioma, A ↑, C ↓; duodenal adenocarcinoma A ↑, B ↓, C ↑; spleen reticulosarcoma A ↓; rabdosarcoma, A and C) | 21, 23, 24 |
|                      | B       | Adult liver, kidney, intestine |                                               |            |
|                      | C       | Adult brain, late fetal liver |                                               |            |
| Phosphorylase        | Liver   | Adult liver              | In hepatomas, the major form is the fetal isozyme                             | 24         |
|                      | Muscle  | Muscle                   |                                               |            |
|                      | Fetal   | Adult brain, fetal tissues|                                               |            |
| Enzyme                             | Source          | mRNA Presence                                      | Notes                                                                 |
|-----------------------------------|-----------------|----------------------------------------------------|----------------------------------------------------------------------|
| Fructose 1,6-diphosphatase         | Liver, skeletal muscle | Liver, kidney, fetal liver                          | Adult kidney and many other tissues (e.g., brain, intestine), fetal liver |
| DNA polymerase                    | Liver, skeletal muscle | Adult liver, fetal liver                            | Adult kidney and many other tissues (e.g., brain, intestine), fetal liver |
| Glutaminase                       | Liver, skeletal muscle | Adult liver only                                   | Hepatoma, mammary carcinoma, sarcoma, kidney adenocarcinoma; and other tumors |
| Carbamyl phosphate synthetase      | Liver, skeletal muscle | Adult liver, fetal liver                           | Rat hepatomas: L ↓, total ↑, K ↓, total ↑                              |
| Glycogen synthase                 | Liver, skeletal muscle | Adult liver, fetal liver                           | Hemoplasms and Erhlich ascites carcinomas L ↓, total ↑              |
| Glycogen phosphorylase            | Liver, skeletal muscle | Adult liver, fetal liver                           | Rat hepatomas: L ↓, total ↑                                          |
| Glucosamine 6-phosphate synthase   | Liver, skeletal muscle | Adult liver, fetal liver                           | Hemoplasms and Erhlich ascites carcinomas L ↓, total ↑              |
Table 5  Other enzymes with altered activities in hepatomas, usually reflecting fetal patterns [22, 32]

| Increased activity                          | Decreased activity                          |
|--------------------------------------------|---------------------------------------------|
| Aldehyde dehydrogenase                     | Xanthine oxidase                            |
| tRNA methylases                            | Dihydrouracil dehydrogenase                 |
| Histaminase (diamine oxidase)               | Pyruvate carboxylase                        |
| Ornithine decarboxylase                     | Phosphoenol pyruvate carboxylase            |
| Ribonucleotide reductase                    | Glucose-6-phosphatase                       |
| Uridine kinase                             | Cytochrome oxidase                          |
| dCMP deaminase                             | Urate oxidase                               |
| dCTP synthetase                            | D-Amino acid oxidase                        |
| γ-Glutamyl transferase                      | L-α-Hydroxy acid oxidase                    |
| Arylamidase                                | Inosine phosphorylase                       |
| Aspartate transcarbamylase                 |                                             |
| Threonine dehydrogenase                    |                                             |
| dTMP synthase                              |                                             |
| dTMP kinase                                |                                             |
| L-Aromatic amino acid decarboxylase        |                                             |
| s-Adenosylmethione synthetase              |                                             |

locations of the hormone genes that have been mapped are listed in Table 6. There is no apparent correlation between the two groups of hormones and the chromosomal locations of their genes.

Cell Surface and Secreted Proteins

Many cell surface changes occur during malignant transformation, generally resulting in the disorganization of the ordered networks of cell surface proteins. These changes are important, as they mediate the interaction of the tumor cell with its environment. Much of the work on cell surface changes has been performed on virally transformed cells cultured in vitro, although the data have general relevance for other tumor cells [47]. The amounts of many membrane-associated proteins are altered following transformation. Fibronectin (chromosomes #2, #8, and #11) [4,48,86], collagen (chromosomes #7 and #17) [92], and membrane-associated actin and myosin are all decreased in many transformed cell lines (Table 7). Certain tumor-specific transplantation antigens (TSTAs) appear following viral transformation. Examples of TSTAs include SV40, feline leukemia and feline sarcoma virus, and Moloney leukemia virus. There are increases in nutrient transport molecules, including the transport of glucose, phosphate, and certain amino acids. cAMP is often decreased in transformed cells. In some cases, this is related to a decreased activity of the plasma membrane adenylate cyclase, and in others to a defect in the regulation of cAMP phosphodiesterase [47].

Hormone receptors may be decreased following transformation, including receptors for epidermal growth factor (chromosome #7), a melanocyte-stimulating activity, transferrin (chromosome #3), catecholamines, and prostaglandin (Table 7). The glycosylation of many glycoproteins are also altered, which may be related to an increased sialylation of the oligosaccharide moieties [49]. Secreted proteins may also be altered following transformation. These changes may include increases in activity of plasminogen activator (chromosome #5) and other proteases and of glycosidases. Plasminogen activators may be responsible for tumor invasiveness and are found in the early embryo, in addition to transformed cells.
Table 6  Chromosomal assignments of hormones involved in tumor expression

| Hormone                      | Locus | Chromosome | Region   | References |
|------------------------------|-------|------------|----------|------------|
| Chorionic gonadotropin       |       |            |          |            |
| α Subunit CGA                | 6     | 6          | 46       |            |
| β Subunit CGB                | 19    | 19         | 46       |            |
| Chorionic somatomammotropin  | CSH   | 17         | q22→q24  | 84, 85     |
| Growth hormone               | GH    | 17         | q22→q24  | 84, 85     |
| Insulin                      | INS   | 11         | p14→p13  | 11, 83     |
| Parathyroid hormone          | PTH   | 11         | p11→pter | 46         |
| Prolactin                    | PRL   | 6          | 82       |            |
| Proopiocortin                | POC   | 2          | p21→p22  | 4, 11      |
| Somatostatin                 | SST   | 3          | q21→qter | 46         |

Table 7  Cell surface or secreted proteins associated with tumor expression [4]

| Protein                              | Locus     | Chromosome |
|--------------------------------------|-----------|------------|
| Collagen [92]                        | COL1A1    | 17         |
|                                      | COL1A1-"like"| 7          |
|                                      | COL1A2    | 7          |
|                                      | COL3A1    | 7          |
| Epidermal growth factor receptor     | EGFR      | 7          |
| Fibronectin system [4, 48, 86]       | FN        | 2          |
|                                     | FNS       | 8          |
|                                     | FN*       | 11         |
| Plasminogen activator                | PLA       | 6          |
| Transferrin receptor                 | TFRC      | 3          |

It is evident that a large number of changes in cell surface proteins may occur following tumorigenesis, and the genes for some of these have now been mapped (Table 7). These proteins are important for cell adhesion and cell–cell recognition, for the uptake of nutrients, and for growth control. Alterations in their expression may therefore be instrumental in the changed ability of the malignant cell to grow and to migrate in the tissue environment. However, the question remains as to whether they are merely a generalized response to the increased metabolic and growth requirements of a tumor.

Other Proteins

Certain other proteins with a role in the protection of the body against disease include interferon and the immunoglobulin and HLA molecules [4, 50]. These proteins may also have some association with protection against cancer; the chromosomal assignments of these genes are listed in Table 8.

Carcinoembryonic Proteins

Some proteins, usually detected antigenically, are commonly found in the fetus and in tumors, but not in adult tissues [51]. These proteins are referred to as carcinoembryonic proteins. This reflects the general phenomenon of dedifferentiation of a slow-growing normal cell to a fast-growing tumor cell with many aspects of fetal
Table 8 Genes associated with protection against disease [4]

| Protein                          | Locus   | Chromosome         |
|----------------------------------|---------|--------------------|
| HLA-A                            | HLA-A   | 6p23→q2105         |
| HLA-B                            | HLA-B   | 6p23→p2105         |
| HLA-C                            | HLA-C   | 6p23→p2105         |
| HLA-D                            | HLA-D   | 6p23→p2105         |
| Immunoglobulin heavy chains      | IGH     | 14                 |
| Immunoglobulin kappa light chains| IGKC, IGKV | 2                  |
| Immunoglobulin lambda light chains| IGLC, IGLV | 22               |
| Interferon-1                     | IF1     | 2p23→qter          |
| Interferon-2                     | IF2     | 5p                 |
| Interferon–fibroblast β-type     | IFB     | 9pter→24           |
| Interferon–leukocyte α-type      | IFA     | 9                  |
| Interferon–immune type           | IFG     | 12                 |
| Interferon production regulator  | IFR     | 16                 |
| Interferon receptor              | IFRC    | 21q21→qter         |

gene expression. Some of the relatively well characterized carcinoembryonic proteins include α-fetoprotein, carcinoembryonic antigen, carcinoembryonic ferritin, etc. [51]. However, none of the genes of these proteins have yet been mapped, although α-fetoprotein (AFP) has been suggested to be on chromosome #4 by homology with the mouse genome [4].

CELL HYBRIDS AND TUMOR SUPPRESSION

When hybrids are formed between tumor cells and normal cells of the same or different species, the transformed phenotype is generally suppressed [52–54]. Suggestions that tumorigenicity is not suppressed in hybrids may reflect rapid chromosomal loss of the normal parental cell in those hybrids. Suppression of tumorigenicity indicates that the cancer defect is recessive in these cases and that it can be corrected by the normal genome regardless of species.

When suppressor chromosomes are lost in hybrids, the transformed phenotype may reappear. In principle, the chromosomal site of a defect causing a specific tumor could thus be mapped by following chromosomal loss, and some have been characterized in this way (Table 9). However, the rapid segregation of chromosomes in interspecific hybrids complicates this strategy [54]. Also, there does not always seem to be an absolute correlation between a single specific chromosome and tu-

Table 9 Chromosomes that suppress or enhance tumorigenicity in somatic cell hybrids [52, 55]

| Hybrid                              | Effect on tumorigenicity | Chromosomes⁰ |
|-------------------------------------|--------------------------|--------------|
| Human × tumorigenic hamster         | Suppression              | 9, 10, 11, 17 |
| Human × tumorigenic hamster         |                          | 10 paired with 4, 7, 8, 9, 11, 13, 17, 7 + 13, 7 + 17, 11 + 13, 11 + 17 |
| Human × tumorigenic hamster         | Enhancement              | 6, 6 + 12    |
| HeLa × human fibroblast             | Suppression              | 11 + 14      |

⁰The gene maps of each of these chromosomes are tabulated in refs. 80 and 93.
Stanbridge et al. [55] generated HeLa × human fibroblast hybrids and found reexpression of tumorigenicity associated with the loss of chromosomes #11 and #14, presumably from the fibroblast parent. The parental origins of the lost chromosomes could not be determined. In human × tumorigenic Chinese hamster hybrids, Klinger and Shows [52] found that human chromosome #2 was lost in all clones that acquired the tumorigenic phenotype. However, chromosome #2 was also preferentially lost in nontumorigenic and low tumorigenicity hybrids, and its possible role in tumorigenicity suppression could not be determined. The loss of chromosomes #9, #10, #11, or #17 were also implicated in the reappearance of tumorigenicity, as were certain combinations of pairs of chromosomes (involving chromosomes #4, #7, #8, #9, #10, #11, #13, and #17). The reappearance of tumorigenicity was enhanced by increased numbers of chromosomes #6, or #6 and #12.

When human tumor cell lines of different origins were fused together, tumorigenicity was sometimes suppressed [54]. Carcinoma × carcinoma and carcinoma × lymphoblastoid hybrids were fully tumorigenic. Carcinoma × sarcoma and carcinoma × melanoma hybrids were not tumorigenic. Thus, at least some tumors have distinct genetic defects that are complementary. HeLa × human fibroblast hybrids were also generated, and a number of phenotypic characteristics typical of tumors could be dissociated from tumorigenicity [54], that is, these characteristics are under separate genetic control and are only secondarily related to the expression of the tumor.

Somatic cell genetics is a valuable tool in the dissection of the chromosomal involvement in the expression of particular tumors. This technique may be used to generate a strategy to dissect the different aspects of tumorigenicity and their interaction. The primary causes of tumorigenesis and some of the secondary effects may thus be distinguished. In suppressed hybrids, the loss of chromosomes involved with both the original defect or with some of the early subsequent events in tumor growth may result in the reappearance of tumorigenicity. This may result in the somewhat complex patterns of chromosomal loss reported for tumor × nontumor hybrids.

ONCOGENES

The significance of viral infection in the etiology of human cancer is generally not known, although an association has been demonstrated for Burkitt’s lymphoma and Epstein-Barr virus in Africans [7], for adult T-cell leukemia and ATLv [56, 57, 89], and has been implicated in some other cases [58]. However, many animal viruses have oncogenic potential in their natural hosts [59], and a number of sites on the human genome are known to be related to viral function or chromosomal integration. Their possible primary or secondary involvement in tumorigenesis is not known and is most unlikely in some cases, but their chromosome locations have been listed in Table 10.

In a rapidly increasing number of cases, single genes have been associated with the ability to transform cell cultures and to induce tumors in experimental animals [60]. These genes have been termed oncogenes and have been characterized in viruses and in tumors of viral and nonviral origin. The DNA tumor viruses (such as SV40, EBV, polyoma) transform cells by means of viral gene products that are essential to the viral replication cycle [61]. However, most of the work on viral oncogenes has been done on retroviruses, and at least 15 retrovirus oncogenes are now known [62]. A number of the human cellular homologs of these retroviral onco-
genes have now been mapped (Table 11). These oncogenes all seem to have been derived originally from the normal genome of the viral hosts, and for each oncogene studied, homologous cellular genes have been detected in various tissues in widely different vertebrate species [68]. Some, but not all, of the cellular homologs (cellular proto-oncogenes) may have a low degree of transcriptional activity in normal cells and seem to play a normal role within the cellular metabolism [60]. Proto-oncogenes from normal human tissues will not transform NIH 3T3 cells, and there is evidence that homologous proto-oncogenes and v-onc's have different DNA sequences [60]. Proto-oncogenes may have to undergo a recombination or mutation-like event before they can transform cells [69, 90, 91]. During transformation by viral oncogenes, the concentration of oncogene product in the cell may increase 100–1000-fold [70]. This overloading of the cell with an excess of an essentially normal cellular protein may be a factor in triggering transformation.

There is some indication that the total number of proto-oncogenes is limited—duplicate and closely related v-onc's have already been identified among the limited number of independently isolated retroviruses analyzed [60]. The proto-oncogenes may comprise a family of genes with related functions, perhaps involved in the regulation of growth and development (since v-onc's disrupt patterns of cellular differentiation during transformation). It may be significant that at least some, if not most, of the v-onc's characterized are tyrosine-specific protein kinases. [60].

Recent recombinant DNA techniques are amenable to the chromosomal mapping of oncogenes (Table 11), and further work in this field is currently in progress. DNA

Table 10 Genetic loci associated with viruses [4]

| Locus                                | Locus assignment |
|--------------------------------------|------------------|
| Adenovirus-12 modification site 1    | A12M1            |
| Adenovirus-12 modification site 2    | A12M2            |
| Adenovirus-12 modification site 3    | A12M3            |
| Adenovirus-12 modification site 4    | A12M4            |
| Baboon M7 virus infection            | BEVI             |
| Epstein-Barr virus nuclear antigen   | EBNA             |
| Herpes simplex virus 1               | HV1S             |
| Human coronavirus 229E sensitivity   | HCVS             |
| Poliovirus sensitivity               | PVS              |

Table 11 Chromosome assignments of human proto-oncogenes

| Locus          | Human chromosome assignment | References |
|----------------|-----------------------------|------------|
| Human c-abl    | 9                           | 64         |
| Human c-fes    | 15                          | 63, 64     |
| Human c-mos    | 8q22                        | 5          |
| Human c-myc    | 6                           | 63         |
| Harvey c-ras   | 11p11→15                    | 65         |
| Kirsten c-ras  | 12                          | 66         |
| Human c-sis    | 22                          | 9, 88      |
| Human c-src    | 20                          | 67         |
from animal and human tumors may be used to transform NIH 3T3 fibroblasts that are consequently tumorigenic in nude mice [71–75]. The presence of oncogenes are thus indicated in tumors independent of the involvement of viruses. Only a minority of human tumors apparently contain oncogenes that are detectable by the NIH 3T3 assay [71, 73]. Oncogenes from different tumors may be the same or highly related, as characterized by restriction endonuclease patterns, as in the case of two colon and two lung carcinomas [73] and for seven human and mouse mammary carcinomas [76]. On the other hand, unique oncogenes were detected in a colon and bladder carcinoma and a promyelocytic leukemia cell line [72] and in at least two bladder carcinomas [73]. In general, however, dissimilar tumor cell lines have unique oncogenes, whereas similar tumors tend to have very similar oncogenes. Lane et al. [77] examined the oncogenes from 20 B and T lymphocytic neoplasms of human and mouse origin. They found that tumors of the same lineage at the same stage of cellular differentiation had very similar oncogenes, whereas tumors at different stages of normal cell differentiation had different oncogenes. Thus, specific transforming genes are activated in tumors at discrete stages of differentiation within these cell lineages, suggesting that these oncogenes may have normal roles in cellular differentiation.

The oncogenes characterized in tumors are most likely derived from normal cells, where they had normal metabolic functions, but were induced, by an unknown series of events, to trigger tumorigenesis. Chang et al. [70] demonstrated that a normal human gene homologous to the viral oncogene Harvey v-ras can induce transformation if made to produce high levels of the gene product. The oncogenes apparently represent a relatively limited class of genes, with similar tumors being caused by the same or very similar oncogenes. However, we may only be observing the limited class of oncogenes that may be detected by the NIH 3T3 assay. At least two of these oncogenes isolated from tumors seem to be analogous to the retrovirus oncogenes [78, 79, 90, 91], and it is of interest to speculate whether tumor and retroviral oncogenes may comprise the same or overlapping classes of genes. A colon/lung oncogene is homologous to the Kirsten sarcoma virus v-ras gene [78], while Parada et al. [79] demonstrated that a human bladder carcinoma oncogene is homologous to the Harvey v-ras.

CONCLUSIONS

A large number of gene products are altered in tumor cells, involving many aspects of cellular metabolism and growth. Many genes with altered expression in tumors have been mapped and are summarized in Tables 3 and 12. Chromosomal changes are frequently observed in tumors. Certain tumors have very specific chromosome alterations associated with them (such as Burkitt’s lymphoma), and these indicate that the tumors are associated with defects in specific gene loci. In other tumors, however, there is no absolute correlation between the tumor type and particular chromosomal abnormalities; instead, there is only a tendency for certain abnormalities to occur relatively frequently. The accumulation of chromosome abnormalities may be a secondary response to loss of growth controls in a cell during tumorigenesis, or perhaps the appearance of chromosome abnormalities disrupts the genetic regulation of a cell, resulting in tumorigenesis. At present, we cannot distinguish between these possibilities.

Many metabolic enzymes have altered expression in tumors (Tables 3–5). These changes mostly seem to reflect altered growth patterns in a tumor cell. Thus, enzyme patterns often change from that of the slowly or nongrowing differentiated adult cell to that of the rapidly growing undifferentiated fetal cell. Tumors from different tissue types often display different enzyme patterns, but these differences
Table 12 The various phenotypes altered in tumors and their chromosomal locations

| Chromosome | Chromosomal abnormalities and changes in gene expression observed in tumors |
|------------|--------------------------------------------------------------------------|
| 1 AK2, PFKM, PGD, AMY1, AMY2, UGP1, SDH, GBA, A12M1, A12M2, A12M3 | chromosomal changes associated with many tumors, including myelomas, lymphomas, carcinomas, various neurogenic tumors, melanomas, etc. |
| 2 IDH1, MDH1, UGP2, AHH, ACP1, POC, FN, IGK, IF1 | chromosomal changes associated with lymphomas, carcinomas, monoclonal gammopathies, melanomas |
| 3 GLB1, SST, TFRC, HV1S | chromosomal changes associated with lymphomas, carcinomas, monoclonal gammopathies, melanomas |
| 4 PPAT | implicated in acute lymphocytic leukemia? |
| 5 ARSB, HEXB, IF2 | chromosomal changes associated with myeloproliferative disorders |
| 6 CGA, SOD2, ME1, PLA, PRL, HLA-A, HLA-B, HLA-C, HLA-D, BEVI, MYB | chromosomal changes associated with ALL, melanomas, ovarian tumors |
| 7 MDH2, UP, GUSB, EGFR, COL1A2, COL3A1 | chromosomal changes associated with various myelomas, CLL, melanomas |
| 8 FNS, MOS, Burkitt’s lymphoma | chromosomal changes associated with various myelomas, CLL, melanomas |
| 9 AK1, AK3, IFA, IFB | chromosomal changes associated with various myelomas, melanomas |
| 10 HK1, PFKF, GOT1 | chromosomal changes associated with various myelomas, melanomas |
| 11 LDHA, CAT, ACP2, ESA4, INS, PTH, FN*, HV1S, HRAS, WAGR | chromosomal changes associated with monoclonal gammopathies, melanomas |
| 12 LDHB, GPD1, BCT1, IFG, KRAS | chromosomal changes associated with chronic lymphocytic leukemia |
| 13 ESD, RB1 | chromosomal changes associated with chronic lymphocytic leukemia |
| 14 CKBB, immunoglobulin heavy chains, EBNA | chromosomal changes associated with the various lymphomas, benign epithelial tumors, ovarian tumors |
| 15 PKM2, IDH2, HEXA, MANA, FES | chromosomal changes associated with acute promyelocytic leukemia |
| 16 TK2, GOT2, ESB3, IFR | chromosomal changes associated with acute promyelocytic leukemia |
| 17 TK1, GALK, GH, CSH, COL1A1, A12M4 | chromosomal changes associated with APL, AML, CML, CLL |

often reflect the isozyme patterns of the normal tissues and of their respective fetal tissues. However, among the multiple enzyme changes observed, it is possible that the altered synthesis of one or a few specific enzymes may in some way affect the metabolic balance of the cell and thus induce tumorigenesis.

Oncogenes represent a class of genes on several chromosomes (Tables 11 and 12) that may, under suitable circumstances, disrupt the metabolism of a cell to induce tumorigenesis. The role of oncogenes in the growth of tumors is not known, but increasing evidence suggests that they may be significant in a number of cases. The study of oncogenes provides an illustration of the potential value of recombinant DNA technology in future investigations of tumors at the molecular level.

All chromosomes are involved in different aspects of tumorigenesis, with either altered gene expression or chromosome abnormalities associated with various tumors (Table 12). However, certain specific chromosome regions seem to be associated with a number of different tumors and with a number of different tumor phenotypes, including chromosomes #3, #8, #14, and #22. For example, small cell lung cancer is associated with a deletion in the 3p14→p23 bands. A translocation involving 3p21 is associated with the familial renal cell carcinoma studied. Chro-
Tumor Phenotype

| Chromosome | Chromosomal abnormalities and changes in gene expression observed in tumors |
|------------|--------------------------------------------------------------------------------|
| 18         | -                                                                             |
| 19         | BCT2, MANB, M7V1, PVS, CGB                                                    |
| 20         | ADA, SRC                                                                      |
|            | chromosomal changes associated with polycythemia vera                        |
| 21         | PFKL, IFRC                                                                    |
|            | chromosomal changes associated with AML, ALL                                  |
| 22         | ARSA, IGL, SIS, Philadelphia chromosome (CML)                                  |
|            | chromosomal changes associated with AML, CML, ALL, meningiomas and other      |
|            | neurogenic tumors                                                             |
| X          | G6PD, OTC, MAOA                                                                |

Gene designations: A12M1, A12M2, A12M3, A12M4—adenovirus-12 chromosome modification sites; ACP1, ACP2—acid phosphatase-1 and -2; ADA—adenosine deaminase; AHH—arylhydrocarbon hydroxylase; AK1, AK2, AK3—adenylate kinase-1, -2, and -3; AMY1, AMY2—α-amylase (salivary and pancreatic, respectively); ARSA, ARSB—aryl sulfatase-A and -B; BCT1, BCT2—branched chain aminotransferase-1 and -2; BEV1—baboon M7 virus infection; CAT—catalase; CGA, CGB—chorionic gonadotropin α and β subunits; CKBB—creatine kinase BB isozyme; COL1A1, COL1A2, COL3A1—collagen; CSH—chorionic somatomammotropin hormone; EBNA—Epstein-Barr virus nuclear antigen; EGFR—epidermal growth factor receptor; ESA4, ES3, ESD—esterase-A4, -B3, -D; FES—human C-fes; FN, FN*—fibronectin system; GALK—galactokinase; GBA—β-glucosidase acid; GH—growth hormone; GGL—β-galactosidase 1; GOL1, GOL2—glutamic oxaloacetic transaminase (soluble and mitochondrial, respectively); GPD1—glycerol-3-phosphate dehydrogenase; GUSB—β-glucuronidase; HEXA, HEXB—hexosaminidase-A and -B; HK1—hexokinase-1; HRAS—Harvey c-ras; HV1S—herpes simplex virus type 1 sensitivity; IDH1, IDH2—iso-1-citrate dehydrogenase (soluble and mitochondrial, respectively); IF1, IF2, IFA, IFB, IFG—interferon-1, -2, leukocyte α-type, fibroblast β-type, and immune type; IFR—interferon production regulator; IFRC—interferon receptor; IGK, IGKL—immunoglobulin kappa chain, lambda chain; INS—insulin; KRAS—Kirsten c-ras; LDHA, LDHB—lactate dehydrogenase-A and -B; M7V1—baboon virus replication; MANA, MANB—α-mannosidase-A and -B; MAOA—monoamine oxidase; MDH1, MDH2—malate dehydrogenase NAD (soluble and mitochondrial, respectively); ME1—malic enzyme (soluble); MOS—human c-mos; MYB—human c-myc; OTC—ornithine transcarbamylase; PFKF, PFKL, PFKM—phosphofructokinase F subunit, liver type, and M subunit; PGD—phosphoglucone dehydrogenase; PKM2—pyruvate kinase (M2); PLA—plasminogen activator; POC—pro-angiogenin; PPAT—phosphoribosyl pyrophosphate amidotransferase; PRL—prolactin; PTH—parathyroid hormone; PVS—poliovirus sensitivity; RB1—retinoblastoma-1; SDH—succinate dehydrogenase; SIS—human c-sis; SOD2—superoxide dismutase (mitochondrial); SRC—c-src; SST—somatostatin; TFRC—transferrin receptor; TK1, TK2—thymidine kinase (soluble and mitochondrial, respectively); UGP1, UGP2—UDP glucose pyrophosphorylase-1 and -2; UP—uridine phosphorylase; WAGR—Wilms’ tumor-aniridia, genitourinary abnormalities, and mental retardation triad.

Chromosome #3 is also associated with various other tumors, such as malignant lymphomas, carcinomas, melanomas (Table 2). In chromosome #8, the q24 band, the location of the c-myc proto-oncogene, is associated with both Burkitt’s lymphomas and familial renal cell carcinoma. About 10% of AML cases have a translocation involving 8q22, and many other tumors are also associated with chromosome #8 abnormalities. The c-mos proto-oncogene has also been localized to the 8q22 band. Chromosome #14 is associated with Burkitt’s lymphoma (q32) and various other tumors. Epstein-Barr virus nuclear antigen (EBNA) and the immunoglobulin heavy chains are also on chromosome #14. Chromosome 22q is associated with the Philadelphia chromosome of CML, with about 70% of meningioma patients, in a few cases of Burkitt’s lymphoma, and with a number of other tumors. The immunoglobulin lambda light chain genes are found on chromosome #22, as is the human proto-oncogene c-sis. It is not known whether the association of different tumors to specific chromosome regions occurs only by chance or whether they reflect certain gene loci, defects in which have profound effects resulting in different tumors. It is also not known whether oncogenes are associated with these specific loci.

Each tumor is probably initiated by defects at a single or a limited number of sites. Defects in these sites have wide-ranging pleiotropic effects involving many genes scattered throughout the genome, resulting in a cascade of primary, second-
ary, and tertiary effects. The expression of a large number of genes controlling the general metabolism and various other cellular processes are thus changed, with transformation and the growth of the tumor consequences of all these changes. Many of the changes in gene expression observed in tumors probably reflect generalized metabolic changes caused by the increased growth of the cell. Although tumors display extensive changes in gene expression, there are no obvious patterns at the chromosome level—the general regulation of tumor growth occurs at a finer level. However, as more genes altered in cancer are mapped and their genetic regulation characterized, their interactions to produce the tumor phenotype will be better understood.

Supported in part by NIH Grants GM 20454, HD 05196, and ACS Grant CD-62.

REFERENCES

1. Mitelman F, Levan G (1981): Clustering of aberrations to specific chromosomes in human neoplasms IV. A survey of 1,871 cases. Hereditas 95, 79–139.
2. Sandberg AA (1980): The Chromosomes in Human Cancer and Leukemia. Elsevier, New York.
3. Rowley JD, Testa JR (1982): Chromosome abnormalities in malignant hematologic diseases. Adv Cancer Res 36, 103–148.
4. Human Gene Mapping Workshop 6 (1982): Cytogenet Cell Genet 32, 1–341.
5. Prakash K, McBride OW, Swan DC, Devare SG, Tronick SR, Aaronson SA (1982): Molecular cloning and chromosomal mapping of a human locus related to the transforming gene of Moloney murine sarcoma virus. Proc Natl Acad Sci, USA 79, 5210–5214.
6. Sakaguchi AY (in press): Genetic organization of human proto-oncogenes. In Oncogenes and Retroviruses. Evaluation of Basic Findings and Clinical Potential.
7. Epstein MA, Achong BG (1979): The relationship of the virus to Burkitt’s lymphoma. In: The Epstein-Barr Virus, Epstein MA, Achong BG, eds. Springer-Verlag, Berlin, pp. 321–337.
8. Erikson J, Finan J, Nowell PC, Croce CM (1982): Translocation of immunoglobulin V\(_H\) genes in Burkitt lymphoma. Proc Natl Acad Sci USA 79, 5611–5615.
9. Swan DC, McBride OW, Robbins KC, Keithley DA, Reddy EP, Aaronson SA (1982): Chromosomal mapping of the simian sarcoma virus onc gene analogue in human cells. Proc Natl Acad Sci USA 79, 4691–4695.
10. Ferrell RE, Riccardi VM (1981): Catalase levels in patients with aniridia and/or Wilms’ tumor: utility and limitations. Cytogenet Cell Genet 31, 120–123.
11. Zabel BU, Naylor SL, Sakaguchi AY, Shows TB, Gusella JF, Housman D, Shine J, Bell GI (1982): High resolution in situ hybridization: Localization of a DNA restriction polymorphism, the human proopiomelanocortin gene, and the human insulin gene. Am J Hum Genet 34, 153A.
12. Johnson MP, Ramsay N, Cervenka J, Wang N (1982): Retinoblastoma and its association with a deletion in chromosome #13: A survey using high-resolution chromosome techniques. Cancer Genet Cytogenet 6, 29–37.
13. Sparkes RS, Sparkes MC, Wilson MG, Towner JW, Benedict W, Murphee AL, Yunis JJ (1980): Regional assignment of genes for human esterase D and retinoblastoma to chromosome band 13q14. Science 208, 1042–1044.
14. Whang-Peng J, Bunn Jr PA, Kao-Shan CS, Lee EC, Carney DN, Gazdar A, Minna JD (1982): A nonrandom chromosomal abnormality, del 3p(14 – 23), in human small cell lung cancer (SCLC). Cancer Genet Cytogenet 6, 119–134.
15. Wake N, Hreshchysyn MM, Piver SM, Matsui S-I, Sandberg AA (1980): Specific chromosomal change in ovarian cancer. Cancer Genet Cytogenet 2, 87–88.
16. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, Jacobs SC, Brown RS (1979): Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 301, 592–595.
17. Bertrand S, Leftheriotis E, Dore JF (1982): Anomalies chromosomiques numeriquest et structurales dans 36 lignees de melanoma malin humain. C R Acad Sci Paris Series III 294, 459-462.

18. Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsatsis AA (1981): Cytogenetic features of human neuroblastomas and cell lines. Cancer Res 41, 4678-4686.

19. Brito-Babapulle V, Atkin NB (1981): Break points in chromosome #1 abnormalities of 218 human neoplasms. Cancer Genet Cytogenet 4, 215–225.

20. Zankl H, Zang KD (1980): Correlations between clinical and cytogenetical data in 180 human meningiomas. Cancer Genet Cytogenet 1, 351–356.

21. Criss WE (1971): A review of isozymes in cancer. Cancer Res 31, 1523–1542.

22. Iben KH, Fishman WH (1979): Developmental gene expression in cancer. Biochim Biophys Acta 560, 243–280.

23. Schapiro F (1973): Isozymes and cancer. Adv Cancer Res 18, 77–153.

24. Tsuiki S (1979): Alteration of isozymes in tumors. GANN Monogr Cancer Res 24, 223–243.

25. Sato S, Sugimura T (1976): Isozymes of carbohydrate enzymes. Meth Cancer Res 12, 259–302.

26. Denton JE, Lui MS, Aoki T, Sebolt J, Takeda E, Eble JN, Glover JL, Weber G (1982): Enzymology of pyrimidine and carbohydrate metabolism in human colon carcinomas. Cancer Res 42, 1176–1183.

27. Westman NG, Marldund SL (1981): Copper-and zinc-containing superoxide dismutase and manganese-containing superoxide dismutase in human tissues and human malignant tumors. Cancer Res 41, 2962–2966.

28. Oberley LW, Buettner GR (1979): Role of superoxide dismutase in cancer: A review. Cancer Res 39, 1141–1149.

29. Weber G (1977): Enzymology of cancer cells (first of two parts). N Engl J Med 296, 486–493.

30. Weber G (1977): Enzymology of cancer cells (second of two parts). N Engl J Med 296, 541–551.

31. Balinski D (1980): Enzymes and isoenzymes in cancer. In: Cancer Markers, S. Sell ed. Humana Press, Clifton, NJ. pp. 191–224.

32. Sun AS, Cederbaum AI (1980): Oxidoreductase activities in normal rat liver, tumor-bearing rat liver, and hepatoma HC-252. Cancer Res 40, 4677–4681.

33. Poplack DG, Blatt J, Reaman G (1981): Purine pathway enzyme abnormalities in acute lymphoblastic leukemia. Cancer Res 41, 4821–4823.

34. Mason ME, Okey AB (1981): Aryl hydrocarbon hydrodase activity in mouse, rat, and human mammary tumors. Cancer Res 41, 2778–2782.

35. Gasa S, Makita A, Kameya T, Kodama T, Araki E, Yoneyama T, Hirama M, Hashimoto M (1980): Elevated activities and properties of arylsulfatases A and B and B-variant in human lung tumors. Cancer Res 40, 3804–3809.

36. Tsuiki S, Katunuma N, Morris HP, Weber G (1979): Purification, properties, and immunotitration of hepatoma glutamine phosphoribosyl-pyrophosphate amidotransferase (amidotransferase, EC 2.4.2.14). Cancer Res 39, 305–311.

37. Dobroszy L, Pellar ZP, Vaughan M, Porter N, Bernacki RJ (1980): Elevation of lysosomal enzymes in primary Lewis lung tumor correlated with the initiation of metastasis. Cancer Res 40, 3281–3285.

38. Okochi T, Seike H, Higashino K, Hada T, Watanabe S, Yamamura Y, Ito F, Matsuda M, Osafune M, Kotake T, Sonoda T (1979): Alteration of hexosaminidase isozymes in human renal carcinoma. Cancer Res 39, 1829–1831.

39. Tanaka T, Kobayashi M, Saito O, Kamada N, Kuramoto A, Usui T (1981): Biochemical activities of lysosomal acid hydrolases in leukemic cells. Clin Chim Acta 117, 121–131.

40. Wilson EL, Becker MLB, Hoal EG, Dowdle EB (1980): Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Cancer Res 40, 933–938.

41. Jerzykowski T, Winter R, Matuszewski W, Piskorska D (1978): A re-evaluation of studies on the distribution of glyoxylases in animal and tumor tissues. Int J Biochem 9, 853–860.

42. Aoki T, Weber G (1981): Carbamoyl phosphate synthetase (glutamine-hydrolyzing): Increased activity in cancer cells. Science 212, 463–465.
43. Knox WE (1976): Enzyme Patterns in Fetal, Adult and Neoplastic Rat Tissues. Karger Press, Basel.

44. Weinhouse S, Shatton JB, Morris HP (1976): Isoenzyme composition, gene regulation and metabolism of experimental hepatomas. In: Cancer Enzymology, J Schultz, F Ahmad, eds. Academic, New York, pp. 41–55.

45. Levine RJ, Metz SA (1974): A classification of ectopic hormone-producing tumors. Ann NY Acad Sci 230, 533–546.

46. Naylor SL, Sakaguchi AY, Kronenburg H, Shen L-P, Rutter W, Chin W, Goodman H (1982): Human genomic organization of glycoprotein and polypeptide hormone genes. Am J Hum Genet 34, 165A.

47. Yamada KM, Pouyssegur J (1978): Cell surface glycoproteins and malignant transformation. Biochimie 60, 1221–1233.

48. Koch GA, Schoen RC, Klebe RJ, and Shows TB (1982): Assignment of fibronectin gene to human chromosome 2 using monoclonal antibodies. Exp Cell Res 141 293–302.

49. Yogeeswaran G, Salk PL (1981): Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science 212, 1514–1516.

50. Naylor SL, Sakaguchi AY, Kronenburg H, Shen L-P, Rutter W, Chin W, Goodman H (1982): Human genomic organization of glycoprotein and polypeptide hormone genes. Am J Hum Genet 34, 165A.

51. Hirai H (1979): Carcinoembryonic proteins. GANN Monogr Cancer Res 24, 181–203.

52. Klinger HP, Shows TB (submitted for publication): Suppression of tumorigenicity in somatic cell hybrids II. Human chromosomes implicated as suppressors of tumorigenicity in hybrids with Chinese hamster (CHO) cells.

53. Sabin AB (1981): Suppression of malignancy in human cancer cells: Issues and challenges. Proc Natl Acad Sci USA 78, 7129–7133.

54. Stanbridge EJ, Der CJ, Doersen C-J, Nishimi RY, Peehl DM, Weissman BE, Wilkinson JE (1982): Human cell hybrids: Analysis of transformation and tumorigenicity. Science 215, 252–259.

55. Stanbridge EJ, Flandermeyer RR, Nelson-Rees WA (1981): Specific chromosome loss associated with the expression of tumorigenicity in human cell hybrids. Somat Cell Genet 7, 699–712.

56. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita K-I, Shirakawa S, Miyoshi I (1981): Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 78, 6476–6480.

57. Yoshida M, Miyoshi I, Hinuma Y (1982): Isolation and characterization of retrovirus from cell line of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 79, 2031–2035.

58. Essex M, Todaro G, zur Hausen H (eds) (1980): Viruses in Naturally Occurring Cancer. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

59. Karpas A (1982): Viruses and leukemia. Am Sci 70, 277–285.

60. Bishop JM (in press): Retroviruses and cancer genes. Adv Cancer Res

61. Klein G (1981): The role of gene dosage and genetic transpositions in carcinogenesis. Nature 294, 313–317.

62. Coffin JM, Varmus HE, Bishop JM, Essex M, Hardy WD Jr, Martin GS, Rosenberg NE, Scolnick EM, Weinberg RA, Vogt PK (1981): Proposal for naming host cell-derived inserts in retrovirus genomes. J Virol 40, 953–957.

63. Dalla-Favera R, Franchini G, Martinotti S, Wong-Staal F, Gallo RC, Croce CM (1982): Chromosomal assignment of the human homologues of feline sarcoma virus and avian myeloblastosis virus onc genes. Proc Natl Acad Sci USA 79, 4714–4717.

64. Heisterkamp N, Groffen J, Stephenson JR, Spurr NK, Goodfellow PN, Soloman E, Carritt B, Bodmer WF (1982): Chromosomal localization of human homologues of two viral oncogenes. Nature 299, 747–749.

65. de Martinville B, Giacolone J, Francke U, Shih C, Weinberg RA (1983): Oncogene from human EJ Bladder carcinoma is located on the short arm of chromosome 11. Science 219, 498–501.

66. Sakaguchi AY, Naylor SL, Shows TB, Tooie JJ, McCoy M, Weinberg RA (in press): Human c-Ki-ras2 proto-oncogene on chromosome 12. Science.

67. Sakaguchi AY, Naylor SL, Shows TB (in press): A human gene homologous to RSV v-src is on chromosome 20. Prog Nucleic Acid Res Molec Biol.
68. Gonda TJ, Sheiness DK, Bishop JM (1982): Transcripts from the cellular homologs of retroviral oncogenes: Distribution among chicken tissues. Molec Cell Biol 2, 617–624.
69. Robinson HL, Blais BM, Tsichlis PN, Coffin JM (1982): At least two regions of the viral genome determine the oncogenic potential of avian leukemia viruses. Proc Natl Acad Sci USA 79, 1225–1229.
70. Chang EH, Furth ME, Scolnick EM, Lowy DR (1982): Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature 297, 479–483.
71. Krontiris TB, Cooper GM (1981): Transforming activity of human tumor DNAs. Proc Natl Acad Sci USA 78, 1181–1184.
72. Murray MJ, Shilo B-Z, Shih C, Cowing D, Ho WH, Weinberg RA (1981): Three different human tumor cell lines contain different oncogenes. Cell 25, 355–361.
73. Perouco M, Goldfarb M, Shimizu K, Lama C, Fogh J, Wigler M (1981): Human-tumor-derived cell lines contain common and different transforming genes. Cell 27, 467–476.
74. Shih C, Shilo B-Z, Goldfarb MP, Dannenberg A, Weinberg RA (1979): Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci USA 76, 5714–5718.
75. Shih C, Padhy LC, Murray M, Weinberg RA (1981): Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 190, 261–264.
76. Lane M-A, Sainten A, Cooper GM (1981): Activation of related transforming genes in mouse and human mammary carcinomas. Proc Natl Acad Sci USA 78, 5165–5189.
77. Lane M-A, Sainten A, Cooper GM (1982): Stage-specific transforming genes of human and mouse B- and T-lymphocyte neoplasms. Cell 28, 873–880.
78. Der CJ, Krontiris TG, Cooper GM (1982): Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci USA 79, 3637–3640.
79. Parada LF, Tabin CJ, Shih C, Weinberg RA (1982): Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297, 474–478.
80. Shows TB, McAlpine PJ (1982): The 1981 catalogue of assigned human genetic markers and report of the nomenclature committee. Cytogenet Cell Genet 32, 221–245.
81. Overbach D, Rutter WJ, Shows TB, Gray P, Goeddel DV, Lawn RM (1981): Leukocyte and fibroblast interferon genes are located on human chromosome 9. Proc Natl Acad Sci USA 78, 2123–2127.
82. Overbach D, Rutter WJ, Cooke NE, Martial JA, Shows TB (1981): The prolactin gene is located on chromosome 6 in humans. Science 212, 815–816.
83. Overbach D, Bell CI, Rutter WJ, Brown JA, Shows TB (1981): The insulin gene is located on the short arm of chromosome 11 in humans. Diabetes 30, 267–270.
84. Overbach D, Rutter WJ, Martial JA, Baxter JD, Shows TB (1980): Genes for growth hormone, chorionic somatomammotropin, and growth hormone-like gene on chromosome 17 in humans. Science 209, 289–292.
85. Harper ME, Barrera-Saldana HA, Saunders GF (1982): Chromosomal localization of the human placental lactogen-growth hormone gene cluster to 17q22→24. Am J Hum Genet 34, 227–234.
86. Klinger HP, Ruoslahti E (1980): Human chromosome 11 is syntenic with human specific fibronectin production in human × mouse cell hybrids. Cytogenet Cell Genet 28, 271–279.
87. Neel B, Jhanwan SC, Chaganti RSK, Hayward WS (in press): Two human c-onc genes are located on the long arm of chromosome 6. Proc Natl Acad Sci USA.
88. Dalla-Favera R, Gallo RC, Giallongo A, Croce CM (1982): Chromosomal localization of the human homolog (c-sis) of the simian sarcoma virus onc gene. Science 218, 686–688.
89. Popovic M, Retz Jr MS, Saragradhan MG, Robert-Guroff M, Kalyanaraman VS, Nakao Y, Miyoshi I, Minowada J, Yoshida M, Ito Y, Gallo RC (1982): The virus of Japanese adult T-cell leukaemia is a member of the human T-cell leukaemia virus group. Nature 300, 63–66.
90. Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR, Chang EH (1982): Mechanism of activation of a human oncogene. Nature 300, 143–149.
91. Reddy EP, Reynolds RK, Santos E, Barbacid M (1982): A point mutation is responsible for...
the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300, 149–152.

92. Huerre E, Junien C, Weill D, Chu M-L, Morabito M, Foubert C, Myers JC, Cong NV, Gross M-S, Pockop DJ, Boule A, Kaplan J-C, de la Chapelle A, Ramirez F (in press): Human type 1 procollagen genes are located on different chromosomes. Proc Natl Acad Sci USA.

93. Shows TB, Sakaguchi AY, Naylor SL (1982): Mapping the human genome, cloned genes, DNA polymorphisms, and inherited disease. In: Advances in Human Genetics, Vol 12, H Harris, K Hirschhorn, eds. Plenum, New York, pp. 341–352.